Ask AI

Applying Emerging B7-H3 ADC Data to Post-Platinum ES-SCLC Decisions

Video
This activity is available for 0.50 CME/CE credit(s).

Released: November 11, 2026

Expiration: May 10, 2027

See Activity Collection

The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the release of new clinical evidence. Watch this video to learn more about the current FDA approvals in ES-SCLC, frontline chemoimmunotherapy options in ES-SCLC, the latest evidence on DLL3-directed T-cell engagers in ES-SCLC, available and emerging treatment options after platinum-based therapy, recent clinical data on the use of investigational B7-H3–directed antibody–drug conjugates, such as ifinatamab deruxtecan, risvutatug rezetecan, tambotatug pelitecan, MHB088C, and elfetabart drozuntecan in ES-SCLC, and a key ongoing phase III trials of B7-H3–directed therapies in ES-SCLC.

Latest Data on Targeting B7 H3 in ES SCLC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with lung cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 64-year-old man has extensive-stage small-cell lung cancer (ES-SCLC) and rapid liver progression 4 months after receiving first-line carboplatin/etoposide plus atezolizumab.

Which of the following findings would you tell this patient, who is interested in participating in a clinical trial, about results reported in the phase II IDEATE-Lung01 trial of the B7-H3–directed antibody–drug conjugate ifinatamab deruxtecan (I-DXd), for patients with SCLC who have received ≥1 prior line of platinum-based therapy?

How confident are you in your answer?
4.

You are discussing a patient with ES-SCLC with your clinical team and considering clinical trial enrollment. Which of the following eligibility requirements would you discuss/highlight about the phase III IDEATE-Lung02 trial?

How confident are you in your answer?